Hydrocortisone Upjohn

Hydrocortisone Upjohn is a prescription injectable formulation containing the corticosteroid hydrocortisone. The product is supplied as an intramuscular or intravenous solution; specific strength and dosage form details are not disclosed in the available data. It belongs to the glucocorticoid class and is marketed in the European Union for professional medical use under a prescription.

Hydrocortisone Upjohn is used in clinical settings where rapid systemic glucocorticoid activity is required. Typical applications include:

- Management of acute adrenal insufficiency or crisis. - Treatment of severe allergic reactions such as anaphylaxis. - Adjunct therapy for asthma or chronic obstructive pulmonary disease exacerbations. - Supportive care in septic shock or severe inflammatory states. - Control of postoperative inflammation and edema. - Management of certain autoimmune or rheumatologic flare-ups.

Adverse reactions to injectable hydrocortisone can vary in frequency and severity.

Common: - Injection site pain or irritation. - Transient increase in blood glucose levels. - Mild electrolyte disturbances, such as sodium retention. - Fluid retention causing mild edema. - Mood changes, including anxiety or insomnia. - Gastrointestinal discomfort.

Serious: - Severe hyperglycemia or diabetic ketoacidosis. - Significant hypertension or cardiovascular events. - Opportunistic infections due to immunosuppression. - Adrenal suppression with abrupt discontinuation. - Severe allergic reaction or anaphylaxis. - Osteonecrosis or rapid bone loss with prolonged use.

When prescribing Hydrocortisone Upjohn, clinicians should consider several safety factors:

- Assess for existing infections; glucocorticoids can exacerbate bacterial, viral, or fungal infections. - Monitor blood glucose in diabetic patients or those at risk for hyperglycemia. - Use caution in patients with uncontrolled hypertension, heart failure, or a history of peptic ulcer disease. - Evaluate for potential adrenal insufficiency before abrupt discontinuation after prolonged therapy. - Consider bone health; long‑term use may increase risk of osteoporosis. - Pregnancy and lactation status should be reviewed, as safety data are limited. - Adjust dosing in elderly patients due to altered pharmacodynamics.

Hydrocortisone Upjohn may interact with several medication classes.

Avoid: - Concurrent use of potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce glucocorticoid levels. - Live vaccines, as immunosuppression can diminish vaccine efficacy and increase infection risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may heighten gastrointestinal bleeding risk.

Use with caution: - Anticoagulants (e.g., warfarin) because glucocorticoids can affect coagulation parameters. - Diabetic agents; hydrocortisone may raise blood glucose, requiring dose adjustments. - Antihypertensive medications, as fluid retention may counteract blood pressure control. - Other immunosuppressants, which can amplify infection risk. - Diuretics, due to potential electrolyte imbalances.